PAR-21-123: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) (PAR-25-060). Status: Due dates in the notice, expires October 20, 2027. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits. Applications closed on October 21, 2024.
From the official notice on Grants.gov, last changed June 20, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNINDS
- Median yearly award$375,078
- Typical project length2 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under PAR-21-123 were run by National Institute of Neurological Disorders and Stroke (NINDS, 27 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-21-123 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-060 | October 22, 2024 | Due dates in the notice, expires October 20, 2027 | Open |
Key dates
| Posted | March 11, 2021 |
|---|---|
| Deadline | October 21, 2024 |
| Archived by Grants.gov | November 20, 2024 |
Who can apply
This opportunity was open to nonprofits.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
Funded under PAR-21-123 so far
NIH funded 27 projects under PAR-21-123 in fiscal 2022 to 2026, at 17 institutions. The median yearly award was $375,078.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| The translational potential of next-generation sporadic mouse and human models of ALS/FTD | Univ of North Carolina Chapel Hill | 2026 | $374,349 |
| Modeling Lennox-Gastaut Syndrome for improved clinical and neurobehavioral outcomes | New York Medical College | 2026 | $406,620 |
| Development of murine glioblastoma model for oncolytic HSV therapy | LSU Health Sciences Center | 2026 | $375,000 |
| Development of a Genetic Rabbit Model of Kcnh2-Mediated Epilepsy, SUDEP, & Long QT Syndrome Type 2 | Upstate Medical University | 2026 | $215,118 |
| Interrogation of Neurological Pathologies Associated with Mutations in Kif1a | Jackson Laboratory | 2026 | $433,867 |
| Human-iPSC derived neuromuscular junctions as a model for neuromuscular diseases. | Case Western Reserve University | 2026 | $390,007 |
| Development of murine glioblastoma model for oncolytic HSV therapy | Augusta University | 2025 | $375,155 |
| Validation of a Translational Model of Chronic Discogenic Low Back Pain | Arizona State University-Tempe Campus | 2025 | $185,142 |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-060, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-21-123 still open?
No. It closed on October 21, 2024. A newer notice is open: PAR-25-060, due dates in the notice, expires October 20, 2027.
Who can apply for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits. The notice adds further conditions, so read its eligibility section.
What is the deadline for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)?
Closed October 21, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-21-123?
NIH RePORTER lists 27 projects funded under PAR-21-123 in fiscal 2022 to 2026, at 17 institutions. The most were at University of Michigan at Ann Arbor, New York Medical College, Upstate Medical University.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)